Rivaroxaban-container1 (Rivaroxaban Container1)
Rivaroxaban Tablet
Product Images NDC 71921-405
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rivaroxaban (NDC 71921-405). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Florida Pharmaceutical Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Rivaroxaban-container2 (Rivaroxaban Container2)
Rivaroxaban-fig-10 (Rivaroxaban Fig 10)
This data appears to be from a clinical trial comparing the drug Rivaroxaban with a placebo. The information includes the number of subjects at risk over specific days from randomization, their cumulative incidence rate, and confidence intervals. The study involves 8313 subjects on Rivaroxaban and 8261 on placebo. Analysis of this data may provide insights into the effectiveness and safety of Rivaroxaban compared to a placebo in the given population.*
Rivaroxaban-fig-11 (Rivaroxaban Fig 11)
Rivaroxaban-fig-12 (Rivaroxaban Fig 12)
Rivaroxaban-fig-2 (Rivaroxaban Fig 2)
Population Description includes PK Fold Change and 90% Confidence Interval for categories such as End-Stage Renal Disease, Renal Impairment (Severe, Moderate, Mild), Age (75-83 years vs. 18-43 years), Body Weight (<=50 kg, 70-80 kg, 120 kg) and Hepatic Impairment (Moderate, Mild). The information provided pertains to differences in parameters such as AUC and Cmax, with references to creatinine clearance levels and a specific medication post hemodialysis for ESRD subjects.*
Rivaroxaban-fig-3 (Rivaroxaban Fig 3)
Rivaroxaban-fig-9 (Rivaroxaban Fig 9)
This text appears to be presenting data on the comparison between rivaroxaban and placebo in clinical trials, with details on outcomes based on age, sex, region, weight, renal function, medical history, surgery history, history of prior heart attack, baseline diabetes status, and baseline creatinine clearance. The results seem to show the efficacy and safety profiles favoring rivaroxaban over placebo based on the given parameters.*
Rivaroxaban-structure (Rivaroxaban Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
